These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 36265311)
21. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502 [TBL] [Abstract][Full Text] [Related]
22. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271 [TBL] [Abstract][Full Text] [Related]
23. Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons. Dabrowski M; Bukowy-Bieryllo Z; Zietkiewicz E Mol Med; 2018 May; 24(1):25. PubMed ID: 30134808 [TBL] [Abstract][Full Text] [Related]
24. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations. McHugh DR; Cotton CU; Hodges CA Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210 [TBL] [Abstract][Full Text] [Related]
26. Stop Codon Context-Specific Induction of Translational Readthrough. Schilff M; Sargsyan Y; Hofhuis J; Thoms S Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356630 [TBL] [Abstract][Full Text] [Related]
27. Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR. Smith E; Dukovski D; Shumate J; Scampavia L; Miller JP; Spicer TP SLAS Discov; 2021 Feb; 26(2):205-215. PubMed ID: 33016182 [TBL] [Abstract][Full Text] [Related]
28. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening. Pibiri I; Lentini L; Tutone M; Melfi R; Pace A; Di Leonardo A Eur J Med Chem; 2016 Oct; 122():429-435. PubMed ID: 27404557 [TBL] [Abstract][Full Text] [Related]
29. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637 [TBL] [Abstract][Full Text] [Related]
30. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations. Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600 [TBL] [Abstract][Full Text] [Related]
31. Recoding of Nonsense Mutation as a Pharmacological Strategy. Temaj G; Telkoparan-Akillilar P; Nuhii N; Chichiarelli S; Saha S; Saso L Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979640 [TBL] [Abstract][Full Text] [Related]
32. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Sharma J; Du M; Wong E; Mutyam V; Li Y; Chen J; Wangen J; Thrasher K; Fu L; Peng N; Tang L; Liu K; Mathew B; Bostwick RJ; Augelli-Szafran CE; Bihler H; Liang F; Mahiou J; Saltz J; Rab A; Hong J; Sorscher EJ; Mendenhall EM; Coppola CJ; Keeling KM; Green R; Mense M; Suto MJ; Rowe SM; Bedwell DM Nat Commun; 2021 Jul; 12(1):4358. PubMed ID: 34272367 [TBL] [Abstract][Full Text] [Related]
33. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
34. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations. Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476 [TBL] [Abstract][Full Text] [Related]
35. Therapeutics based on stop codon readthrough. Keeling KM; Xue X; Gunn G; Bedwell DM Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318 [TBL] [Abstract][Full Text] [Related]
38. Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR. Yeh JT; Hwang TC J Physiol; 2020 Feb; 598(3):517-541. PubMed ID: 31585024 [TBL] [Abstract][Full Text] [Related]
39. Properties of Non-Aminoglycoside Compounds Used to Stimulate Translational Readthrough of PTC Mutations in Primary Ciliary Dyskinesia. Dabrowski M; Bukowy-Bieryllo Z; Jackson CL; Zietkiewicz E Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066907 [TBL] [Abstract][Full Text] [Related]
40. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. Du M; Keeling KM; Fan L; Liu X; Bedwell DM J Biol Chem; 2009 Mar; 284(11):6885-92. PubMed ID: 19136563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]